Geron's Upcoming Investor Conferences: A Beacon of Hope for Blood Cancer Patients and Investors Alike

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, has announced its participation in three major healthcare investor conferences in March 2025. These conferences provide an opportunity for the company to update investors on its progress, pipeline, and future prospects. As an investor relations expert, I am excited to see Geron taking this proactive approach to engage with the investment community.



The company will participate in fireside chats at the following events:

1. TD Cowen 45th Annual Health Care Conference - March 3rd at 3:10pm ET in Boston, MA
2. Leerink Global Healthcare Conference - March 10th at 3:00pm ET in Miami, FL
3. Barclays 27th Annual Global Healthcare Conference - March 11th at 10:30am ET in Miami, FL

Live webcasts of each fireside chat will be available through the Investors & Media section of Geron’s website under Events, with replays archived for 30 days.

Geron's upcoming participation in these conferences is a testament to its commitment to transparency and investor relations. By presenting at these prestigious events, the company can showcase its innovative pipeline, including its first-in-class telomerase inhibitor, RYTELO (imetelstat), which is approved in the United States for the treatment of certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia.



The company's management team will likely discuss its ongoing clinical trials, such as the IMpactMF Phase 3 trial for relapsed/refractory myelofibrosis (R/R MF) and the IMerge Phase 3 trial for lower-risk MDS patients who are relapsed, refractory, or ineligible for erythropoiesis stimulating agents (ESAs). These trials have the potential to expand Geron's pipeline and drive future growth.

In addition to updating investors on its clinical progress, Geron may also provide insights into its commercial strategy, financial performance, and cash position. As of June 30, 2024, the company had approximately $430.4 million in cash, cash and equivalents, and marketable securities, indicating a strong financial foundation for its ongoing operations and clinical development efforts.

Geron's participation in these investor conferences is an important milestone for the company and its stakeholders. By engaging with investors, analysts, and industry professionals, Geron can build and strengthen relationships, generate enthusiasm for its mission and pipeline, and ultimately drive long-term stock price appreciation.

As an investor, I am encouraged by Geron's proactive approach to investor relations and its commitment to updating the investment community on its progress. The company's upcoming participation in these conferences is a beacon of hope for blood cancer patients and investors alike, as it continues to work towards changing the course of blood cancer and creating value for its shareholders.